4.5 Article

Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors

期刊

GENE THERAPY
卷 17, 期 7, 页码 872-879

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2010.27

关键词

wtAAV; rAAV; particle-to-infectivity ratio; specific activity

资金

  1. US National Institutes of Health [GM071023, GM075019, DK062345, HL077322]

向作者/读者索取更多资源

Viral vectors derived from adeno-associated viruses (AAVs) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently shown immunological complications in clinical trials, highlight the necessity to define the specific activity of vector preparations beyond current standards. In this report, we determined the infectious, physical and genome-containing particle titers of several wild-type AAV type 2 (wtAAV2) and recombinant AAV type 2 (rAAV2) preparations that were produced and purified by standard methods. We found that the infectivity of wtAAV2 approaches a physical-to-infectious particle ratio of one. This near-perfect physical-to-infectious particle ratio defines a 'ceiling' for the theoretically achievable quality of recombinant AAV vectors. In comparison, for rAAV2, only approximately 50 out of 100 viral particles contained a genome and, more strikingly, only approximately 1 of the 100 viral particles was infectious. Our findings suggest that current strategies for rAAV vector design, production and/or purification should be amenable to improvements. Ultimately, this could result in the generation of near-perfect vector particles, a prospect with significant implications for gene therapy. Gene Therapy (2010) 17, 872-879; doi:10.1038/gt.2010.27; published online 25 March 2010

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biotechnology & Applied Microbiology

High Capsid-Genome Correlation Facilitates Creation of AAV Libraries for Directed Evolution

Mathieu Nonnenmacher, Harm van Bakel, Roger J. Hajjar, Thomas Weber

MOLECULAR THERAPY (2015)

Article Medicine, Research & Experimental

Effectiveness of gene delivery systems for pluripotent and differentiated cells

Kleopatra Rapti, Francesca Stillitano, Ioannis Karakikes, Mathieu Nonnenmacher, Thomas Weber, Jean-Sebastian Hulot, Roger J. Hajjar

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2015)

Review Biotechnology & Applied Microbiology

Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids

Kyle Chamberlain, Jalish Mahmud Riyad, Thomas Weber

HUMAN GENE THERAPY METHODS (2016)

Editorial Material Biochemistry & Molecular Biology

Do we need marker gene studies in humans to improve clinical AAV gene therapy?

T. Weber

GENE THERAPY (2017)

Article Cardiac & Cardiovascular Systems

Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure

Shin Watanabe, Kiyotake Ishikawa, Kenneth Fish, Jae Gyun Oh, Lukas J. Motloch, Erik Kohlbrenner, Philyoung Lee, Chaoqin Xie, Ahyoung Lee, Lifan Liang, Changwon Kho, Lauren Leonardson, Maritza McIntyre, Scott Wilson, R. Jude Samulski, Evangelia G. Kranias, Thomas Weber, Fadi G. Akar, Roger J. Hajjar

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

Review Biotechnology & Applied Microbiology

Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure

Michael G. Katz, Anthony S. Fargnoli, Thomas Weber, Roger J. Hajjar, Charles R. Bridges

HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2017)

Article Biotechnology & Applied Microbiology

A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity

Kyle Chamberlain, Jalish M. Riyad, Tyrone Garnett, Erik Kohlbrenner, Ananda Mookerjee, Firas Elmastour, Ludovic Benard, Jiqiu Chen, Thierry VandenDriessche, Marinee K. Chuah, Ali J. Marian, Roger J. Hajjar, Priyatansh Gurha, Thomas Weber

HUMAN GENE THERAPY (2018)

Article Urology & Nephrology

Protein S Protects against Podocyte Injury in Diabetic Nephropathy

Fang Zhong, Haibing Chen, Yifan Xie, Evren U. Azeloglu, Chengguo Wei, Weijia Zhang, Zhengzhe Li, Peter Y. Chuang, Belinda Jim, Hong Li, Firas Elmastour, Jalish M. Riyad, Thomas Weber, Hongyu Chen, Yongjun Wang, Aihua Zhang, Weiping Jia, Kyung Lee, John C. He

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)

Review Cardiac & Cardiovascular Systems

Human Cardiac Gene Therapy

Kiyotake Ishikawa, Thomas Weber, Roger J. Hajjar

CIRCULATION RESEARCH (2018)

Article Medicine, Research & Experimental

Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption

Alejandro Orlowski, Michael G. Katz, Sarah M. Gubara, Anthony S. Fargnoli, Kenneth M. Fish, Thomas Weber

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)

Article Cardiac & Cardiovascular Systems

Identification of Genes and Pathways Regulated by Lamin A in Heart

Jordi Coste Pradas, Gaelle Auguste, Scot J. Matkovich, Raffaella Lombardi, Suet Nee Chen, Tyrone Garnett, Kyle Chamberlain, Jalish Mahmud Riyad, Thomas Weber, Sanjay K. Singh, Matthew J. Robertson, Cristian Coarfa, Ali J. Marian, Priyatansh Gurha

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

Review Biochemistry & Molecular Biology

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Jalish M. Riyad, Thomas Weber

Summary: Recombinant adeno-associated virus has become the most popular gene therapy vector in the last two decades, with higher doses increasing the risk of adverse events. FDA has recently approved AAV gene therapy for two rare genetic disorders, highlighting the need for better vectors to achieve therapeutic levels with lower doses. The review discusses cellular roadblocks that AAV must overcome and recent advancements in AAV biology that can improve vector performance for safer gene therapy.

GENE THERAPY (2021)

Review Cardiac & Cardiovascular Systems

Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer

Michael G. Katz, Anthony S. Fargnoli, Sarah M. Gubara, Kenneth Fish, Thomas Weber, Charles R. Bridges, Roger J. Hajjar, Kiyotake Ishikawa

JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2019)

Review Cardiac & Cardiovascular Systems

Cardiac gene therapy with adeno-associated virus-based vectors

Kyle Chamberlain, Jalish M. Riyad, Thomas Weber

CURRENT OPINION IN CARDIOLOGY (2017)

暂无数据